The NAXIVA trial (Phase II Neoadjuvant Study of Axitinib for Reducing Extent of Venous Tumour Thrombus in Renal Cancer with Venous Invasion, NCT03494816) was a phase II, single-arm, multicentre study investigating the use of neoadjuvant axitinib, a vascular endothelial growth factor receptor (VEGFR)-directed tyrosine kinase inhibitor (TKI), to reduce the ccRCC VTT. The gene discussed is KDR; the disease is nonpapillary renal cell carcinoma.